Brief report : medical assistance in dying in patients with lung cancer

Article indépendant

MOORE, Sara | THABET, Chloé | WHEATLEY-PRICE, Paul

Introduction: Medical assistance in dying (MAiD) was legalized in Canada in 2016. Cancer accounts for 60% to 65% of MAiD cases. Lung cancer, the most common cause of cancer death, is expected to makeup a large number of MAiD cases. Lung cancer treatment has advanced in recent years; however, involvement of oncology specialists and use of systemic therapy in patients who receive MAiD are unknown. Methods: All patients with lung cancer referred to the Champlain Regional MAiD Program from June 17, 2016, to November 30, 2020, were reviewed. Baseline demographics, diagnostic, referral, and treatment details were collected by retrospective review. Coprimary end points were the proportion of patients who met a medical oncologist or who received systemic therapy. Results: During the study period, 255 patients with cancer underwent MAiD. Of these, 45 (17.6%) had lung cancer, comprising our final study population. Baseline characteristics: median age 72 years, 64% female, 85% former or current smoking history, 82% non-small cell, 4% small cell, and 13% clinical diagnosis without biopsy. Most patients (78%) were seen by a medical oncologist, though only 16 (36%) received systemic therapy for advanced disease. In subpopulations of interest, 45% of patients with programmed death-ligand 1 greater than or equal to 50% received immunotherapy and 75% with an oncogenic driver mutation received targeted therapy. There were 26 patients (58%) who had a documented discussion with their oncologist regarding the transition to best supportive care. Conclusions: Most patients with lung cancer are assessed by an oncology specialist before MAiD, though less than half received systemic therapy. Among patients with more treatable forms of lung cancer, many patients still undergo MAiD without accessing, or in some cases being assessed for, these treatment options.

https://www.sciencedirect.com/science/article/pii/S266636432200008X

Voir la revue «JTO clinical and research reports, 3»

Autres numéros de la revue «JTO clinical and research reports»

Consulter en ligne

Suggestions

Du même auteur

Brief report : medical assistance in dying in...

Article indépendant | MOORE, Sara | JTO clinical and research reports | n°2 | vol.3

Introduction: Medical assistance in dying (MAiD) was legalized in Canada in 2016. Cancer accounts for 60% to 65% of MAiD cases. Lung cancer, the most common cause of cancer death, is expected to makeup a large number of MAiD cases...

Medical assistance in dying in patients with ...

Article indépendant | THABET, Chloe | JCO oncology practice | n°9 | vol.19

PURPOSE: Medical assistance in dying (MAiD) was legalized in Canada in 2016. To date, patients with cancer account for 69% of MAiD deaths, yet little information is available about these patients. We reviewed disease and treatment...

Delivering hospital-based pediatric palliativ...

Article indépendant | DOHERTY, Megan | JCO global oncology | n°6

PURPOSE: The majority of pediatric cancer deaths occur in low- and middle-income countries (LMICs). Pediatric palliative care (PPC) focuses on relieving physical, psychosocial, and spiritual suffering throughout the continuum of c...

De la même série

Brief report : medical assistance in dying in...

Article indépendant | MOORE, Sara | JTO clinical and research reports | n°2 | vol.3

Introduction: Medical assistance in dying (MAiD) was legalized in Canada in 2016. Cancer accounts for 60% to 65% of MAiD cases. Lung cancer, the most common cause of cancer death, is expected to makeup a large number of MAiD cases...

Chargement des enrichissements...